A researcher prepares a sample inside a laboratory at BeiGene's research and development centre in Beijing, China, on Thursday, May 24, 2018. Biotech company BeiGene is worth about $9 billion on the Nasdaq, a multiple of about seven times its 2016 IPO, and its experimental cancer drugs are being closely watched globally. Photo: Bloomberg

Investment bankers are quitting Goldman, Citigroup for biotech riches in Hong Kong

Topic |   Banking & Finance

TOP PICKS

A researcher prepares a sample inside a laboratory at BeiGene's research and development centre in Beijing, China, on Thursday, May 24, 2018. Biotech company BeiGene is worth about $9 billion on the Nasdaq, a multiple of about seven times its 2016 IPO, and its experimental cancer drugs are being closely watched globally. Photo: Bloomberg
READ FULL ARTICLE